Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Inflammation × Tablets × Clear all

Phase

Phase EARLY_PHASE1 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1 Breast 1

Conditions

Breast Neoplasms 9 Multiple Myeloma 3 Melanoma 3 Venous Thromboembolism 1 Triple Negative Breast Neoplasms 1 Thrombocythemia, Essential 1 Stem Cell Transplant Complications 1 Skin Toxicity 1 Skin Neoplasms 1 Resectable Pancreatic Ductal Adenocarcinoma 1 Renal Insufficiency 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1 Polycystic Ovary Syndrome 1 Obesity 1 Neoplasms 1 Myeloproliferative Disorders 1 Meningioma 1 Lymphoma, Mantle-Cell 1 Lung Neoplasms 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia, B-Cell 1 Leukemia 1 Inflammation 1 Head and Neck Neoplasms 1

Interventions

XENP 1595 2 salicylsalicylic acid 1 microcrystalline cellulose 1 ginger extract 1 epigallocatechin gallate 1 dapagliflozin 1 Tablets 1 Sulindac 1 Specimen Handling 1 Sodium Salicylate 1 Radiotherapy, Conformal 1 Pregabalin 1 Omeprazole 1 Losartan 1 Ketorolac 1 Interleukin 1 Receptor Antagonist Protein 1 Infliximab 1 Etanercept 1 Atorvastatin 1 Ascorbic Acid 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06150898 2025-06-13

KePreSt

Jules Bordet Institute

Phase 2 Recruiting

Breast Neoplasms, Inflammation, Obesity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡